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In the present study, a pH responsive polylactic acid coated 
SBA-15 functionalized with 3-aminopropyl triethoxysilane is 
reported. PLA has been coated on the functionalized SBA-15  
by formation of amide linkage between amine functionalized 
SBA-15 and PLA. The amide linkage is confirmed by FTIR 
spectroscopic data. The materials are well characterized by FTIR, 
SEM, EDAX and XRD data. Using the PLA coated functionalized 
SBA-15 the controlled release of the drug ibuprofen has been 
studied. The successful delivery of ibuprofen has been achieved 
on the basis of its pH response. 
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Mesoporous materials with regular geometries are 
drawing a lot of attention owing to their great 
potential in practical applications such as catalysis, 
adsorption, sensing, medical usage ecology, 
nanotechnology, chromatography, photonic devices, 
electronic devices, drug delivery and energy storage.1-8 
Over the past 30 years, there has been rapid growth in 
the area of drug delivery because drug delivery can 
bring solutions for both commercial and therapeutic 
problems associated with health care products. Apart 
from polymers and nanomaterials, microparticles,9 
porous materials,10 smart materials like hydrogels11 
are also being used as drug carrier for drug delivery. 
Among the various materials used in drug delivery, 
mesoporous materials have other notable properties 
which include large surface area, adjustable pore 
diameters, modifiable surface properties and 
biocompatibility that are essential for drug delivery 
applications. Also, the pore size and pore volume of 
the mesoporous materials can be altered, and 
depending on the size and the surface chemistry of the 
pores, increased dissolution rate or sustained release 
of drugs can be achieved.12,13  
The first report on ibuprofen loaded into 
mesoporous silica material MCM-41 was published 
by Vallet Regi in 2001.14 Since then, numerous 
articles have been published on these materials with 
modified pore size and chemical modifications of the 
surfaces.15 Because of the high solubility of highly 
porous (p-Si> 70%) materials in simulated body fluids 
(except in the simulated gastric fluid), many of them 
were used as drug carrier. Slowing et al.16 discussed 
the advantages of using mesoporous materials for 
several drug delivery applications. The exciting 
progress on using mesoporous materials to penetrate 
various cell membranes in animal and plant cells is 
also reported. 
Owing to the wide range of useful properties, these 
porous carriers have been used in pharmaceuticals for 
many purposes including the development of floating 
drug delivery systems, sustained drug delivery 
systems. Various types of pores like open, closed, 
transport and blind pores in the porous solid allow 
them to adsorb drugs and release them in a more 
reproducible and predictable manner.10  
The triblock copolymer template made the 
mesoporous silica material, SBA-15, has large, 
controlled pore size and highly ordered hexagonal 
topology. These properties have opened the way to 
intriguing experiments inside the resulting channel 
structures.17 By anchoring various functional groups 
on the internal surfaces, the sorption capacity and 
behavior of SBA-15 could be substantially altered. 
SBA-15 has a nanosilicate mesoporous composition 
which is prepared by surfactant templating 
mechanism. The structure of mesopore can be 
controlled by the volume of the precursors added  
such as copolymers and inorganic components.18 The  
most commonly used structure directing copolymer is 
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene 
oxide), commercially known as P123. 
Mesoporous material SBA-15 has been used for 
both traditional drug delivery systems and 
implantable local drug delivery devices. These local 
drug delivery systems can be useful in bone tissue 
repair.19 Song et al.20 reported controlled drug delivery 
using functionalized SBA-15 in 2005.20 SBA-15 
materials were functionalized with amine groups by 
post-synthesis and one-pot synthesis. SBA-15 




functionalized by one-pot synthesis is found to be 
more favorable for the adsorption and release of drug 
due to the balance of electrostatic interaction and 
hydrophilic interaction between the drug and the 
functionalized SBA-15 matrix. Michal Moritz et al. 21 
reported the application of SBA-15 mesoporous 
material as carrier for drug formulation systems. 
SBA-15 mesoporous material has been used as a 
matrix in three different drug formulations as 
powders, granules and tablets. Submicron particles 
with modified surface were synthesized by Shen et al.22 
by a simple one-pot synthesis approach and used as 
drug carrier for controlled release. They coated MgO 
on the surface of SBA-15 and used the material as a 
drug carrier in pH responsive drug delivery.22  
Polymeric materials are very attractive for various 
applications due to ease of preparation and flexibility 
towards alteration of chemical and physical properties 
via molecular synthesis. In order to be used for 
controlled drug delivery, the polymer must be 
chemically inert and free of leachable impurities with 
appropriate physical structure, minimal undesired 
aging, and be readily processable. Some examples are 
poly(2-hydroxy ethyl methacrylate),23 poly(N-vinyl 
pyrrolidone),24 poly(methyl methacrylate),25 poly(vinyl 
alcohol),26 poly(acrylic acid),27 polyacrylamide,28 
poly(ethylene-co-vinyl acetate),29 poly(ethylene 
glycol),30 poly(methacrylic acid),31 polylactides 
(PLA),32 polyglycolides (PGA),33 polyanhydrides,34 
and polyorthoesters.35 Originally, polylactides and 
polyglycolides were used as absorbable suture material, 
and it was a natural step to work with these polymers in 
controlled drug delivery systems. The greatest 
advantage of these degradable polymers is that they are 
broken down into biologically acceptable molecules 
that are metabolized and removed from the body via 
normal metabolic pathways.36 
SBA-15 can be synthesized by the hydrothermal 
process through liquid templating mechanism.37 It 
possesses ordered non-intersecting hexagonal 
channels. The walls of these mesoporous materials are 
amorphous silica. SBA-15 has got higher mechanical 
and thermal stability as compared to MCM-41 
(Mobile Crystalline Material).38  
In this work, for the synthesis of SBA-15, pluronic 
123 (P123) was used as template material and 
tetraethylorthosilicate (TEOS) as silica source 
(Scheme 1). For drug encapsulation and coating, 
polymeric drug carrier (i. e., polylactic acid PLA) was 
chosen. Polymeric drug carriers are biocompatible, 
pH responsive, and target specific, zero release profile 
before reaching the target. The polymeric coating was 
required because unmodified MSNs cannot release 
the drugs. In human bodies, the pH is different in 
different parts and hence we can easily target systems 
by pH responsive polymeric coating. Ibuprofen was 
loaded on amine functionalized SBA-15. After the 
absorption of ibuprofen into the pores, it was 
centrifuged and the supernatant was analysed under 
UV visible spectroscopy at 263.5 nm to evaluate 
ibuprofen adsorbed on the silica nanoparticles. The 








coated with PLA by forming an amide linkage 
between –COOH group of PLA and –NH2 group 
ibuprofen loaded SBA-15 (Scheme 1), leading to the 
successful incorporation of PLA in SBA-15. The amide 
formation was confirmed by FTIR spectroscopy.  
The peak at 1650 cm-1 in IR spectrum of the PLA 
coated SBA-15 confirmed the successful formation of 
amide linkage.  
 
Experimental 
All chemicals used, viz., tetraethyl orthosilicate 
Si(OC2H5)4 (TEOS, >99%), pluronic 123 (MW = 
5800), amino propyl triethoxysilane (APTES), 
polylactic acid, dichloromethane, DCC and DMAP 
(amide coupling agents), were of analytical grade. 
FTIR spectra were recorded on a RXI Perkin-Elmer 
spectrometer using KBr pellets. The surface 
morphology was studied by scanning electron 
microscopy (SEM) (JEOL JSM 6360, Japan). The 
structural characteristics were analyzed by XRD data 
recorded on a Shimadzu X-ray diffractometer (XRD 
6000, Japan) using a monochromatic X-ray beam 
from CuKα radiation.  
SBA-15 was synthesized by the procedure 
previously reported under hydrothermal  
conditions using a triblock organic copolymer as  
a template.17 In the typical synthesis, triblock  
copolymer (4 g), poly(ethyleneoxide)-poly(propylene 
oxide)-poly(ethylene oxide) (EO20-PO70-EO20) 
(Pluronic P123, MW = 5800) was dispersed in doubly 
distilled water (40 g) and 2 M aqueous HCl (120 mL) 
was added with stirring at ambient temperature  
(35 °C) for 3 h. Finally, tetraethylorthosilicate (4 g) 
was added to the homogeneous solution with stirring 
at 40 °C for 24 h to form a gel. The resultant gel was 
allowed to stand at 100 °C for 48 h in a Teflon Parr 
reactor, which led to crystallization under static 
hydrothermal conditions. The white solid product was 
filtered off, washed with warm distilled water for 
several times, and dried at 150 °C overnight. The solid 
product obtained was calcined at 540 °C in air for  
24 h to remove the organic template. 
For the preparation of aminopropyltriethoxysilane 
functionalized SBA-15, a suspension of aminopropyl-
triethoxysilane (APTES) (0.45 g, 2 mmol) and 
calcined SBA-15 (1 g) in toluene (20 mL) was 
refluxed with continuous stirring under an inert 
atmosphere for 24 h. The resulting mixture was 
cooled to room temperature, filtered, washed with dry 
toluene and diethyl ether, and then dried under 
vacuum at ambient temperature. The dried material 
was further subjected to soxhlet extraction with dry 
dichloromethane for 24 h to remove the unreacted 
APTES. Finally, the functionalized SBA-15 solid 
product was dried at 70–90 °C under vacuum for 12 h. 
Next, ibuprofen was loaded into the pores of  
amine functionalized SBA-15. Amine functionalized 
SBA-15 (100 mg) was soaked in concentrated 
ibuprofen solution (30 mg mL-1) in hexane. The 
solution was sonicated for 1 min in a bath sonicator 
and kept in a shaker for 24 h at room temperature. 
After the absorption of ibuprofen into the pores, it was 
centrifuged and the supernatant was analysed under 
UV visible spectroscopy at 263.5 nm to evaluate 
ibuprofen adsorbed on the silica nanoparticles. 
For the preparation of PLA coated SBA-15, 
polylactic acid was dissolved in dichloromethane. 
DCC (Dicyclohexylcarbodiimide) and DMAP were 
used as coupling agent which helps in the formation 
of amide linkage between amine functionalized  
SBA-15 and PLA. Then the ibuprofen loaded SBA-15 
was added to the above solution and stirred overnight. 
The resultant product was filtered and washed with 
water in order to remove the urea byproduct. The 
product was dried in oven at 100 °C. 
 
Results and discussion 
The SEM images of SBA 15 before and after PLA 
coating shows rod-like shaped structure (Fig. 1(a) and 
(b)). The irregularity in the shape of the particle may 
be due to the increase in temperature during the 
surfactant removal step. The morphological studies 
show that the SBA-15 retained the structure even after 
drug loading and PLA coating.  
The ordered mesoporous structure was confirmed 
by XRD characterization (Fig. 2). The 100 and 200 
reflections represent the presence of mesopore and 
also confirm the hexagonal array of pores. All the 
samples show a well resolved reflection, indicating 
excellent structural ordering. SBA-15 mesoporous 
molecular sieves exhibited narrow pore size 
distribution. This indicates that all the materials even 
after the modification with amine, exhibit a well 
ordered two-dimensional hexagonal structure with 
linear arrays of pores which are arranged in regular 
intervals.  
From the high intensity peak from the 100 plane, it 
was confirmed that the pore is free of any particles or 
surfactant templates (Fig. 2(a)). After ibuprofen 
loading, the diffraction peak intensities become a little 
weaker (Fig. 2(b & c)), indicating the presence of 
organic molecules inside the mesopores. The pore 




size of ~8 nm calculated from the XRD is found 
suitable for drug loading and other applications 
including catalysis. 
From the SEM-EDAX analysis at various points of 
the sample, the loading of drug on PLA matrix was 
confirmed. The typical vibration modes of SBA-15 at 
3328 cm-1 for OH and at ~1076 cm-1 for Si-O-Si and 
the sharp peak at 945 cm-1 for Si-OH are seen in the 
case of both pure SBA-15 and amine functionalized 
SBA-15. In the case of amine functionalized SBA-15, 
a small shoulder at 2934 cm-1, ascribed to the CH 
stretching frequency of the aminopropylate triethoxy 
silane and a peak at 1515 cm-1, due to the NH bending 
were observed. It is interesting to note that the 
intensity of the OH band significantly decreases after the 
end capping process, confirming that the free surface 
silanol groups present in the pore walls of ligand 
immobilized SBA-15 are capped with TMS groups. 
To study the in vitro release of ibuprofen, ibuprofen 
loaded PLA coated mesoporous nanoparticles were 
mixed in different ranges of buffer solutions starting 
from pH 5 to 8 and shaken in a water bath maintained 
at 35 °C. In each trial, after a few minutes, aliquots 
were taken out, centrifuged and analyzed under  
UV visible spectroscopy at 263.5 nm. The PLA 
coated functionalized SBA-15 acts as a pH responsive 
shell, ensuring the release of the drug loaded  
under acidic conditions (Table 1). From Table 1 it  
is seen that the ibuprofen release was almost 100% 
within two hours. The release of drug was slow  
when the pH of the medium increased.This may be 
due to the protonation rate of amide nitrogen of the 
PLA coated functionalized SBA-15 under different 
pH conditions.  
The main disadvantage is at undesirable pH, 
leaching will occur. Liu et al.39 reported polyvinyl 
pyridine coated MSNs as a pH responsive drug 
delivery system. At high pH, this system formed a gel 
like structure stopping the drug release.39 The drug 
ibuprofen release studies were carried out under 
different pH conditions. Mild acidic condition 
promotes protonation of amide NH leading to 
swelling of polymeric matrix. This resulted in the free 
release of drug molecules. Hence, altering pH can 
achieve a controlled release of the drug. 
To conclude, a new method of coating PLA on 
amine functionalized mesoporous silica is reported. 
The drug ibuprofen release studies were carried out 
under different pH conditions. Mild acidic condition 
favours the successful release of the drug molecule.  
 
 
Fig. 1 — SEM images of functionalized SBA-15 before coating (a), and, (b) after PLA coating. 
 
 
Fig. 2 — XRD patterns of (a) SBA-15 before coating, (b) SBA-15 
after ibuprofen loading, and, (c) SBA-15 after PLA coating. 
Table 1 – pH responsive drug release of ibuprofen by 
PLA coated functionalized SBA-15 
No. pH value Time (h) Drug released (%) 
1 5 2 98 
2 6 2 82 
3 7 2 67 
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